share_log

Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $52

Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $52

Needham维持对Harmony Biosciences的买入,将目标股价上调至5
Benzinga ·  05/01 05:34

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $50 to $52.

尼德姆分析师阿米·法迪亚维持Harmony Biosciences(纳斯达克股票代码:HRMY)的买入并将目标股价从50美元上调至52美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发